"Angiogenesis"; axitinib is approved for renal cell carcinoma, bevacizumab is approved for metastatic colon, lung, renal, ovarian, GBM, and sunitinib for renal cell carcinoma, GIST and target is VEGF. The gene discussed is VEGFA; the disease is renal cell carcinoma.